The authors demonstrate the use of a simple, universal G-protein-coupled receptor (GPCR) assay to screen for agonists for a specific GPCR. Cells stably expressing a green fluorescent protein (GFP)-labeled β-arrestin fusion protein and the vasopressin V2 receptor (V2R) were used in a high-content screening (HCS) assay to screen a small peptide library for V2R agonists. Cells were treated with the peptides at a final concentration of 500 nM for 30 min. Agonist stimulation causes V2R internalization into endosomes. GFP-β-arrestin remains associated with the V2R in endosomes, resulting in a fluorescent pattern of intracellular spots. Assay plates were automatically imaged and quantitatively analyzed using an HCS imaging platform and a fast turnkey image analysis application optimized for detection of receptor activation and intracellular spots. Hits were further evaluated to determine their potency. The combination of unique biology, automated high-content analysis, and a powerful means of validating hits results in better leads. (Journal of Biomolecular Screening 2005:476-484) 
G -PROTEIN-COUPLED RECEPTORS (GPCRs) are the largest family of cell-surface molecules involved in signal transmission. 1 The broad variety of extracellular activators or ligands that signal through GPCRs underscores the physiological importance of this receptor class, and GPCRs are the target of the majority of current therapeutic agents on the market. [1] [2] [3] The number of GPCRs within the human genome is estimated to be as great as 1000, based on analysis of predicted GPCR gene structures. 2 Of the approximately 650 identified GPCR genes, only about 190 of these have been categorized as "known" GPCRs, which are activated by some 70 identified ligands. 2 Thus, GPCRs represent a class of receptors that have major potential for the discovery of new, physiologically promising drugs.
Activation of a GPCR by the binding of an agonist results in the activation of its associated heterotrimeric G-protein, leading to a cascade of intracellular signaling events. 1, [4] [5] [6] Signaling can occur from either the G-protein's Gα or Gβγ subunit. The 20 known Gα subunits are categorized into 4 families (Gα i , Gα s , Gα q , and Gα 12/13 ), with each family having certain characteristic signaling pathways. 4, 6, 7 Different GPCRs interact with specific types of Gα sub-units, resulting in different subsequent downstream effector enzyme systems being activated. 4, 6, 7 There are several challenges in drug discovery for GPCRs. First, assaying for agonist activation of a GPCR based on the receptor's downstream signaling means that different assays are required for the different potential signaling pathways. A universal assay for GPCR activation that did not depend on the specifics of signaling pathways would simplify compound screening efforts to identify agonists or antagonists. Second, a screening assay that yielded more information on the compound and its effects on the cells would increase the efficiency of screening campaigns by allowing the easy elimination of compounds that were false positives or had cytotoxic effects. A further challenge beyond characterizing the biology, physiology, and pharmacology of receptors for which ligands are known and beyond developing new drugs that affect the functioning of these receptors is in identifying ligands for the many GPCRs for which no ligands are known (i.e., "orphan" receptors) and identifying their physiological function as well as their role in the pathophysiology of particular diseases. Thus, a desirable assay platform and technology is one that can address the twin challenges of (1) studying and discovering drugs for known GPCRs with an efficient universal assay with low false-positive rates, as well as (2) being able to de-orphan orphan GPCRs. Such a screening technology would be a valuable drug discovery tool that could be used to realize the immense potential of this lucrative class of targets. The combined use of 2 recent innovative technological developments, Xsira Pharmaceuticals's (formerly Norak Biosciences) Transfluor ® technology and Cellomics's High Con-tent Screening (HCS) assay tools, can fulfill these needs and have the promise of efficiently improving the quality of information and leads from screens for GPCR agonists and antagonists. [8] [9] [10] [11] Ligand binding to GPCRs results not only in the activation of G-protein-dependent signaling pathways but also in the induction of pathways that modulate the magnitude and duration of the receptor response. Cytoplasmic proteins, termed arrestins, rapidly translocate to and bind the activated receptor at the plasma membrane and sterically uncouple the receptor from its cognate Gprotein, thereby attenuating the signaling event. 12 This process, common to nearly all GPCRs, is termed desensitization. Arrestins also mediate the internalization of the activated receptors by targeting them to clathrin-coated pits and may also play a role in the extent to which the receptors recycle back to the plasma membrane (resensitization) or are degraded in lysosomes (down-regulation). 12 The interaction of β-arrestin2 with GPCRs during the internalization process has led the GPCRs to be divided into 2 classes: A and B. 13, 14 For class A GPCRs (such as the β2-adrenergic receptor, µopioid receptor, endothelin type A receptor, dopamine D1A receptor, and α1B adrenergic receptor), the β-arrestin2 translocates to the GPCR readily but also dissociates from the GPCR soon after directing the receptor to clathrin-coated pits and is not bound to the GPCR when it is delivered to endosomes. 14 For class B GPCRs (such as the angiotensin II type 1A receptor, neurotensin receptor 1, vasopressin V2 receptor, thyrotropin-releasing hormone receptor, and neurokinin 1 receptor), the β-arrestin2 remains associated with the GPCR during internalization and is found in the cell associated with endosomes. 14 These regulatory events, such as agonistinduced arrestin binding and internalization, are natural indicators of GPCR activation and can be used to develop universal assays for their activation. 10, 11, [15] [16] [17] [18] This phenomenon of β-arrestin translocation to the plasma membrane and its subsequent trafficking with activated GPCRs to clathrin-coated pits and/or endocytic vesicles can be detected using a fluorescently labeled β-arrestin. 10, 11, 19 Xsira Pharmaceuticals's Transfluor ® technology uses chimeric proteins of βarrestin fused with green fluorescent protein (GFP) to monitor the activation of GPCRs. 10 The use of GFP fusion proteins with βarrestin has been shown to have the same pharmacological response as GPCR activation and trafficking. 10, 11, [19] [20] [21] Thus, agonistinduced GPCR activation can be assayed by measuring GFP-βarrestin intracellular redistribution using quantitative fluorescence imaging methods. 10, [22] [23] [24] The advantage of Transfluor ® technology is that it can be used as a universal screen for GPCR activation and is not dependent on the GPCR's specific G-protein signaling pathway, the nature of the activating ligand, or the sequence of the receptor. 10, 11 Currently, translocation of GFP-β-arrestin has been demonstrated in the literature for more than 70 different GPCRs. 11 Because β-arrestin is a key protein in the regulation of most GPCRs, this assay approach can also be used to screen for and identify agonists for orphan GPCRs. 10, 11, 25 Because the β-arrestin is fluorescently labeled with GFP, the challenges associated with finding appropriate fluorescent probes for the assayed targets are avoided, making the assay easier to set up and run; all that is needed are cells transfected to express the GFP-β-arrestin and the GPCR under investigation.
Assaying for GPCR activation using Transfluor ® technology requires the ability to quantitatively analyze the spatial redistribution of GFP-β-arrestin, and the HCS automated, quantitative, cellbased assay approach is well suited to do this. 10, [22] [23] [24] HCS is defined as the automation of the high-content biological investigation of cells, and the phrase high content is used to refer to the quantitative analysis of processes that are defined spatially and temporally in the context of the structural and functional integrity of individual or clusters of cells. 8, 9 In practice, high-content screening involves a fluorescence cell-based assay in which the cells are automatically imaged and analyzed using quantitative fluorescence microscopy. Cells are labeled with fluorescent probes whose fluorescence emissions reflect the cell's phenotype, physiological state, or cellular distributions of targets. Cells are typically arrayed in a microplate such as a 96-or 384-well plate. These sample plates are automatically delivered to an HCS imaging instrument, such as Cellomics, Inc.'s ArrayScan ® HCS Reader, which is based on a fluorescence microscope. Fluorescence images of the cells in each well are automatically acquired and analyzed on-the-fly by proprietary, flexible, turnkey image-processing algorithms; these imageprocessing algorithms are called "BioApplications" by Cellomics. 8, 9 This automated imaging and analysis of multiple multiwell plates can rapidly generate a large amount of data, which consist of both images and the results of their quantitative analysis. For ease of use in data management and to enable the user to interact with the results, HCS also requires informatics software that automatically and seamlessly archives the data, enables the user to interact with it, and assists in his or her scientific decision making. In addition to the advantages of HCS's automation and objective quantitation capabilities, it also has the ability where multiple assays can be simultaneously multiplexed. This is achieved by the availability of the entire visible spectrum of light-enabling multiplefluorescence probes that emit at different wavelengths to be simultaneously used to label different targets in the same cell. The simultaneous quantitative assaying, analysis, and correlation of all the multiplexed targets lead to the high-information content nature of the HCS assay approach. HCS is being rapidly adopted by scientists involved in basic as well as drug discovery research in the academic, biotechnology, and pharmaceutical industry settings. HCS has also been applied to the quantitation of a wide range of cell biological problems, [15] [16] [17] [18] [22] [23] [24] [26] [27] [28] [29] [30] [31] [32] [33] [34] and commercial tools are available to enable users to do so. 8, 9 In this article, we demonstrate the use of HCS with Transfluor ® technology to screen a small peptide library for agonists for the vasopressin V2 receptor, a class B GPCR. We demonstrate that this is an easy-to-use, efficient, and robust assay technology that yields highly qualified leads.
MATERIALS AND METHODS

Cells and reagents
The small peptide library that was screened, LOPAP (Library of Pharmacologically Active Peptides), was purchased from Sigma Chemical (St. Louis, MO). Additional test compounds, including arginine 8 vasopressin, arginine 8 vasotocin, oxytocin, 1-34 peptide of parathyroid hormone (PTH), porcine dynorphin A, and endomorphin 2, were also purchased from Sigma. The human vasopressin V2 receptor (V2R) was subcloned into pcDNA3.1zeo (Invitrogen, Baltimore, MD). 35 The development of U2OS cells stably expressing the GFP-β-arrestin fusion protein and the V2R has been previously described. 10 The stable cell line was routinely cultured in Eagle's minimum essential medium (EMEM; BioWhittaker, Walkersville, MD), supplemented with 10% fetal calf serum (BioWhittaker Inc.), 10 µg/mL gentamicin solution (Life Technologies, Grand Island, NY), 2 mM L-glutamine solution (BioWhittaker), 10 mM HEPES (BioWhittaker), 0.4 mg/mL zeocin (Invitrogen), and 0.4 mg/mL G418 (Invitrogen). For the experiments described, cells were plated in 96-well, black, clearbottomed Packard ViewPlate ™ microplates (PerkinElmer, Boston, MA) at a density of 17,000 cells per well.
Sample preparation
A high-content screen was conducted on the LOPAP library to identify agonists for the vasopressin V2 receptor. Peptides were supplied at a concentration of 100 µM in 100% DMSO. Three replicate 96-well assay microplates were plated with U2OS cells stably expressing GFP-β-arrestin fusion protein and the V2R at a density of 17,000 cells per well. Aliquots of 5 µL of 20× stocks of an agonist/compound library intermediate plate were transferred to each well of the cell assay plate, which contained 95 µL of serum-free media. The 3 cell assay plates were incubated at 37°C for 30 min before fixation with 2% formaldehyde and labeling of the cell nuclei with 5 µg/mL of the DNA-binding dye Hoechst 33342 (Molecular Probes, Eugene, OR). Plates were sealed and could be stored at 4°C. The final peptide concentration in the cell assay plate was 500 nM, and the final DMSO concentration was 0.5%, which has been demonstrated to have no effect on the translocation response (C. L. Cowan, unpublished observations).
The LOPAP library contains 60 different pharmacologically active peptides. The layout of the 3 replicate sample plates was the same. Cells in 60 wells of the sample plates were treated with the peptides from the LOPAP library. Twelve wells on each plate were negative controls and were not treated with any compound (buffer only). Thirteen other wells were positive controls and were treated with 111 nM arginine 8 vasopressin (AVP), an agonist for the V2R; as will be seen below from the measured EC 50 values, this represents a saturating concentration of the agonist. The wells of 1 row of each plate were also treated with decreasing concentrations of AVP to produce a 12-point AVP dose-response curve.
Imaging and analysis
Images and data of the cells were automatically obtained using an ArrayScan ® V TI HCS Reader, produced by Cellomics, Inc. (Pittsburgh, PA). Appropriate filter sets for detection of the 2 fluorophores were used, and the different fluorescent signals were recorded in 2 different image collection channels of the ArrayScan V TI HCS Reader (i.e., channel 1 contained the blue fluorescent Hoechst 33342-labeled nuclear images, and channel 2 contained the green fluorescent GFP-β-arrestin images). A 20× 0.4 numerical aperture microscope objective was used for the imaging, 1 field was imaged per well, and Cellomics's Spot Detector BioApplication was used to acquire and analyze the images onthe-fly after optimization of the application's protocol settings. For these experiments, the Spot Detector BioApplication used the Hoechst-labeled nuclei to identify individual cells and then automatically counted and analyzed the GFP-labeled spots associated with each cell. In addition to the number of spots and the sum of their areas and pixel intensities, the BioApplication also reports properties of the individual nuclei such as their area.
RESULTS
Experiment conducted
To identify agonists for the vasopressin V2 receptor, a quantitative, cell-based high-content screen was conducted on the small peptide library LOPAP. Three replicate 96-well microplates were plated with U2OS cells stably expressing GFP-β-arrestin fusion protein and the V2R, and each plate was treated with the peptides from the library at a final concentration of 500 nM at 37°C for 30 min. The cells were then fixed and their nuclei labeled with Hoechst 33342. The plates were automatically imaged on the Cellomics ArrayScan V TI HCS Reader and analyzed on-the-fly by the Spot Detector BioApplication. Figure 1 shows images of cells acquired on the ArrayScan V TI HCS Reader treated with different concentrations of AVP. At the lowest concentration of AVP (0.62 pM), the GFP fluorescence has a diffuse, intracellular, cytoplasmic distribution, and few punctate objects are seen. At 457 pM AVP, some punctate intracellular spots are seen. At the highest concentration of 111 nM AVP, the intracellular GFP are in punctate spots, which are the GFP-βarrestin associated with intracellular endosomes. These images show that a dose-dependent effect to AVP could be seen in images acquired by the ArrayScan V TI HCS Reader.
Quantitative analysis using the Spot Detector BioApplication
Cellomics has developed a multichannel, image-processing, and analysis HCS software module, known as the Spot Detector BioApplication, that enables the quantitative analysis of fluorescently labeled spots in cells. This BioApplication was designed for flexibility, enabling it to be easily configured and ap-plied toward many different biological situations that have a punctate intracellular phenotype. Output features that are automatically measured include the total intensity of spots in the image, the number of spots in the image, the number of spots per cell, and the total intensity of spots per cell, and these properties were used to quantitatively identify responders in this screening assay.
The bottom row of Figure 1 shows the results from the automated image analysis, shown by colored overlays, done by the Spot Detector BioApplication. Each cell's domain is shown by the yellow overlay, and the individual spots associated with each cell are shown in orange. As can be seen in the raw images, the 0.62-pM vasopressin image hardly had any spots compared to the AVP- treated image, and the few spots that were detected were smaller and had lower intensity. The 457-pM vasopressin image had more spots detected per cell, and the 111-nM vasopressin image had the most number of spots that were identified and analyzed. As will be shown later in this article, the 457-pM vasopressin dose is slightly less than measured EC 50 values (which ranged from 0.55-0.87 nM), and at this concentration, approximately half the cells had some spots, although the number of spots per cell was less than seen with the maximal 111-nM vasopressin dose. Overall, Figure 1 demonstrates that the ArrayScan V TI HCS Reader with the Spot Detector BioApplication can detect and quantitatively analyze the changing numbers of spots in the images resulting from changes in agonist concentration.
Evaluating assay performance
To evaluate the performance of the assay, we first evaluated the ability of the different measured features to reflect the biology. We also simultaneously monitored the assay for any anomalous sample preparation or cytotoxic problems. This was followed by assessments of the assay's robustness for screening and its speed. From the AVP dose-response wells in the sample plates, we evaluated the total intensity of the spots and the number of spots for the whole image as well as per cell. These are plotted in Figure 2A spot total intensity per cell, and the number of spots per cell were 0.729 nM, 0.573 nM, 0.711 nM, and 0.552 nM, respectively. These EC 50 values are similar to each other and also similar to published EC 50 values for vasopressin. [36] [37] [38] [39] [40] This validates that this assay approach works and can accurately quantify the biology and that the different properties measured by the Spot Detector BioApplication can be used to assess the pharmacological properties of the agonists.
In addition to automatically reporting the number of spots and their intensities, the number of cells (i.e., number of nuclei) and the nuclear area are also simultaneously measured and reported. A loss in cell number or a change in the nuclear area can be used as indicators of toxicity, sample preparation problems, or other anomalous effects. We found that the number of cells per image for the different AVP concentrations remained constant (~194 ± 1 cells/ field). Similarly, the mean nuclear area for the different AVP concentrations remained constant (~271 ± 2 pixels). These 2 features, measured over all the wells for all 3 plates, were also extremely constant (number of cells = 194 ± 10 with percent coefficient of variation [%CV] = 5% and mean nuclear area = 274 ± 7 with %CV = 3%; values are means from wells from all 3 plates ± standard deviation); this indicates that anomalous effects did not occur for any of the different conditions, compounds, or treatments tried.
The values from the untreated negative control and treated (111 nM AVP) positive control wells on each plate were used to assess the Z′ values for the spot total intensity and the spot number measurements ( Table 1 ). The Z′ value is a metric used to assess the robustness of an assay for screening and is the normalized 3 standard deviation window between the negative and positive control values. 41 The Z′ values shown for the different measured features in Table 1 are either close to or greater than 0.5, indicating that this is an excellent assay for screening. 41 Other robustness criteria shown in Table 1 include the assay's signal/background (i.e., foldincrease in response) and signal/noise; both of these are large for all 4 measured features, further demonstrating this assay's robustness.
The assay is also reasonably rapid. The image analysis occurred automatically on-the-fly while the plate was being scanned and imaged, and the plate scan time plus quantitative analysis time using this BioApplication was~6 min per plate. In other words, approximately 6 min after commencing a plate's imaging, the results from the quantitative analysis of the entire plate were available.
Identifying hits
To objectively assess the results from scanning these plates, hit criteria were established. A hit was defined if the measured feature (spot total intensity or spot number per image or per cell) was beyond the 99% confidence interval. In other words, the compound was a hit if the measured feature's value was beyond the range set by the mean ± 3 times the standard deviation of the negative control value (untreated wells). By this definition, only 3 compounds registered as hits on each of the 3 plates: arginine 8 vasopressin, arginine 8 vasotocin, and oxytocin. Figure 3A shows the spot total intensity per image value for all 3 plates, with the hits clearly identified. To further investigate reproducibility of the assay results and to confirm the hits, a linear regression analysis was done where the spot total intensity per image for each well in plate B was plotted against the spot total intensity per image for the same well in plate C (Fig. 3B) . The correlation between the results from the 2 plates was extremely tight (R = 0.987), signifying a high degree of reproducibility between replicate sample plates. The hits are also clearly seen in this plot and are distinct from the negative controls and nonresponders.
Determining EC 50 concentrations of hits
Follow-up experiments were done to further confirm and qualify the hits, as well as some of the nonresponders. For these, 12point dose-response experiments were conducted, in which 4 wells of a 96-well plate got each concentration of each compound and then were imaged and analyzed as before. The mean spot total intensity per image and standard error of the mean from the 4 wells for each concentration were calculated and plotted in Figure 4 for the 3 hit compounds. These 3 hit compounds showed a dose dependency on their ability to induce spot formation, further confirming them as V2R agonists. Vasopressin was the most potent agonist, with an EC 50 value of 0.865 nM, which was similar to the previously measured values (Fig. 2) . Vasotocin was less potent, with an EC 50 of 3.64 nM, and oxytocin was the least potent, with an EC 50 of 270 nM. The oxytocin also caused a lower maximal response compared to the other 2 agonists. The potency rankings and EC 50 values of these 3 agonists are in close agreement with published reports. 42, 43 Several nonresponding compounds were similarly tested over a 4-decade concentration range (up to 10 µM), and none showed any dose-dependent ability to induce spot formation, further confirming them as nonresponders (not shown).
DISCUSSION AND CONCLUSIONS
We have demonstrated a robust, cell-based HCS assay to identify agonists for the vasopressin V2 receptor, using Xsira Pharma- Summary assay robustness statistics shown for spot total intensity and number of spots derived from the negative (untreated) and positive (111 nM AVP) control wells from each of the 3 replicate sample plates. The mean ± standard error of the 3 sample plates is shown for each statistic. The statistic definitions are as follows: Z′ = 1 -((3σ c+ + 3σ c-)/|µ c+ -µ c-|), where µ c+ is the mean positive control signal, σ c+ is the standard deviation of the positive control signal, µ c-is the mean negative control signal, and σ c+ is the standard deviation of the negative control signal. 41 ceuticals's Transfluor ® technology. This assay had high Z′ values and good signal/noise and signal/background values. Screening the LOPAP peptide library for vasopressin V2 receptor agonists identified vasopressin and 2 additional responders, vasotocin and oxytocin, both of which have amino acid sequences similar to arginine 8 vasopressin. The potency for the 3 hits was ranked, and the EC 50 values varied~300-fold, in agreement with published reports. 43 Vasopressin was the most potent, and oxytocin was the least. Given the availability of cells stably expressing the GFP-βarrestin fusion protein and the vasopressin V2 receptor, this assay was easy to set up and run. The only fluorescent labeling needed was the labeling of the cell nuclei with Hoechst 33342, which is a simple step. The HCS tools offered by Cellomics provided a seamless, automated integration of data acquisition, analysis, and archiving and enabled us to access the analyzed data rapidly and with relative ease. The simultaneous reporting of the number of cells and their nuclear area enabled monitoring for any cytotoxic, sample preparation, or other problems. For the screening assays conducted, the number of cells and their nuclear area remained constant for all the conditions and compound treatments tried, indicating a lack of sample preparation or cytotoxic problems. In The hits (circled) correspond to vasopressin, vasotocin, and oxytocin, respectively. Hits were defined as being beyond the 99% confidence interval of the negative control (horizontal purple line). The other data points shown that are greater than the 99% confidence limit are from the positive control wells. (B) Linear regression analysis between plates B and C, demonstrating reproducibility of the hit results. The spot total intensity per image data from these 2 plates were plotted against each other for each well. The positive controls and the 3 hits were clearly distinct from the negative control and nonresponder population. The correlation between the results from the 2 plates was extremely tight (R = 0.987). This demonstrates the reproducibility of the assay results and the hits between replicate sample plates. . 4 . An additional experiment was run to further confirm and profile the 3 hit compounds and compare them with nonresponding compounds. A 12-point dose-response series was done for the 3 hit compounds. Each data point is the mean ± standard error from 4 replicate wells for each concentration for each compound. The 3 hit compounds showed a dose-dependent ability to induce spot formation, further confirming them as vasopressin V2 receptor (V2R) agonists. The EC 50 value for vasopressin was similar to earlier results (Fig. 2) . The potencies of the 3 agonists were vasopressin > vasotocin > oxytocin. The nonresponding compounds similarly tested (from 1-10 addition to the number of cells and the nuclear area, the multiplexing capability of HCS assays also enables the simultaneous monitoring and correlation of other targets and physiological phenomena in the same cells, although this was not explicitly demonstrated in the experiments described. 8, 9, 17, 27, 30 This would enable further monitoring for cytotoxicity effects or of correlating GFP-β-arrestin appearance in spots with other downstream signaling phenomena. 8, 9, 27 These result in higher information content derived from the screen and thus better leads. This additional information could also facilitate the automatic elimination of false positives from the data.
The described experiments were for screening for agonists of a class B GPCR. 14 Similar screens have been carried out using a combination of Transfluor ® technology and HCS to identify agonists and antagonists for the β2 adrenergic receptor, which is a class A GPCR. [22] [23] [24] A similar assay or quantitative analysis could be done using conventional fluorescence microscopy or confocal microscopy. However, the quantitative results described were automatically obtained and analyzed from a 96-well microplate imaged on an ArrayScan HCS Reader with the Spot Detector BioApplication. The automatic, nonsubjective, turnkey imaging and quantitative analysis procedure took 6 min per plate and demonstrates the potential of the automated HCS assay approach. It would also be more difficult to do a similar assay with existing fluorescence reader technology or flow cytometry in an automated manner. Thus, this automated, nonsubjective, easy-to-use assay procedure provides information-rich, quantitative results and demonstrates the potential of the HCS assay approach in identifying and characterizing GPCR agonists and antagonists. The combination of unique biology, automated high-content analysis, and a powerful means of validating hits results in highly qualified leads. These highly qualified leads enhance drug discovery efforts by providing better leads that ultimately lead to lower attrition.
